Sartorius Stedim Biotech/ FR0013154002 /
| 2024-05-22 9:27:32 PM | Chg. - | Volume | Bid- | Ask- | Market Capitalization | Dividend Y. | P/E Ratio |
|---|---|---|---|---|---|---|---|
| 210.0000USD | - | 30 Turnover: 6,300 |
-Bid Size: - | -Ask Size: - | 18.27 bill.USD | - | - |
Assets
| 2017 IFRS in mill. EUR |
2018 IFRS in mill. EUR |
2019 IFRS in mill. EUR |
2020 IFRS in mill. EUR |
2021 IFRS in mill. EUR |
|||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Property and Equipment | 331.3000 | 436 | 546.6000 | 644.4000 | 928.4000 | ||||||
| Intangible Assets | 172.9000 | 177.5000 | 180.1000 | 633.5000 | 684.4000 | ||||||
| Long-Term Investments | 11.8000 | 5.6000 | 15.1000 | 13.5000 | 14.8000 | ||||||
| Fixed Assets | - | - | - | - | 2,495.5000 | ||||||
| Inventories | 185.6000 | 252 | 328.2000 | 472.3000 | 783 | ||||||
| Accounts Receivable | 211.6000 | 220.2000 | 220.8000 | 256.9000 | 356 | ||||||
| Cash and Cash Equivalents | 32.6000 | 24 | 27.6000 | 59.8000 | 223.6000 | ||||||
| Current Assets | 490.8000 | 552.5000 | 633.8000 | 875.2000 | 1,455.6000 | ||||||
| Total Assets | 1,403.9000 | 1,571.5000 | 1,820.4000 | 3,069.3000 | 3,951.1000 | ||||||
Liabilities
| 2017 IFRS in mill. EUR |
2018 IFRS in mill. EUR |
2019 IFRS in mill. EUR |
2020 IFRS in mill. EUR |
2021 IFRS in mill. EUR |
|||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Accounts Payable | 118 | 154.6000 | 196.6000 | 307 | 471.2000 | ||||||
| Long-term debt | 92.5000 | 67 | 130.6000 | 819 | 1,003.6000 | ||||||
| Liabilities to Banks | 223.4000 | 171.1000 | 214.8000 | 861.3000 | - | ||||||
| Provisions | 87.5000 | 87.5000 | 100.5000 | 197.3000 | 208.1000 | ||||||
| Liabilities | 524.4000 | 526.6000 | 642.8000 | 1,586.4000 | 2,217.9000 | ||||||
| Share Capital | 18.4000 | 18.4000 | 18.4360 | 18.4360 | 18.4360 | ||||||
| Total Equity | 879.5000 | 1,044.9000 | 1,177.6000 | 1,482.9000 | 1,655.9000 | ||||||
| Minority Interests | 7.4000 | 8.5000 | 18.8000 | 22.9000 | 77.4000 | ||||||
| Total liabilities equity | 1,403.9000 | 1,571.5000 | 1,820.4000 | 3,069.3000 | 3,951.1000 | ||||||
Income Statement
| 2017 IFRS in mill. EUR |
2018 IFRS in mill. EUR |
2019 IFRS in mill. EUR |
2020 IFRS in mill. EUR |
2021 IFRS in mill. EUR |
|||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenues | 1,081 | 1,212.2000 | 1,440.6000 | 1,910.1000 | 2,887 | ||||||
| Depreciation (total) | - | - | - | - | - | ||||||
| Operating Result | 221.7000 | 300.2000 | 332 | 471.8000 | 865.4000 | ||||||
| Interest Income | - | - | - | - | -218.7000 | ||||||
| Income Before Taxes | 220.6000 | 284.5000 | 317.6000 | 482.6000 | - | ||||||
| Income Taxes | 56.8000 | 74.6000 | 81.4000 | 122.1000 | 232.4000 | ||||||
| Minority Interests Profit | -2.7000 | -1.9000 | -1.6000 | -2.7000 | -1.4000 | ||||||
| Net Income | 161.1000 | 208.1000 | 234.6000 | 357.8000 | 414.3000 | ||||||
Per Share
Cash Flow
| 2017 IFRS in mill. EUR |
2018 IFRS in mill. EUR |
2019 IFRS in mill. EUR |
2020 IFRS in mill. EUR |
2021 IFRS in mill. EUR |
|||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash Flow from Operating Activities | 174.7000 | 227.3000 | 310.1000 | 416.9000 | 696 | ||||||
| Cash Flow from Investing Activities | -194.9000 | -176.5000 | -136 | -150.5000 | -323.6000 | ||||||
| Cash Flow from Financing | 16.6000 | -59.6000 | -122.2000 | 234.1000 | -71.7000 | ||||||
| Decrease / Increase in Cash | -3.6000 | -8.8000 | 3.1000 | 29.8000 | - | ||||||
| Employees | 5,092 | 5,637 | 6,203 | 6,900 | 10,409 | ||||||
